Table 1.
Validated list of metabolites changed in human vitreous samples when comparing controls to patients with PDR and in mouse eyes from normoxia and OIR models at P17
| Metabolite | Human PDR | OIR P17 mouse | ||||
|---|---|---|---|---|---|---|
| First set | Second set | |||||
| Fold change | p-value | Fold change | p-value | Fold change | p-value | |
| Methioninea | 1.7 | 0.0387 | 3.0 | 0.0002 | 1.1 | 0.6436 |
| Allantoina | 2.5 | 0.0003 | 1.7 | 0.0081 | 1.4 | 0.2349 |
| Decanoylcarnitinea | 1.7 | 0.0028 | 1.4 | 0.0054 | Below limit of detection | |
| Argininea,b | 1.8 | 0.0387 | 1.9 | 0.0081 | 2.2 | 0.0109 |
| Prolinea,b | 3.3 | 0.0003 | 5.7 | <0.0001 | 5.0 | 0.0002 |
| Citrullinea,b | 1.5 | 0.0201 | 1.5 | 0.0211 | 2.0 | 0.0003 |
| Ornithinea,b | 1.1 | 0.0346 | 1.2 | <0.0001 | 1.3 | 0.0084 |
| Octanoylcarnitinea,b | 2.2 | 0.0200 | 1.7 | 0.0005 | 3.0 | 0.0004 |
| Lysineb | 1.3 | 0.0573 | 1.1 | 0.2383 | 1.5 | 0.0024 |
| Succinateb | 1.4 | 0.6180 | 1.3 | 0.8580 | −1.6 | 0.0226 |
| Pantothenateb | Below limit of detection | 1.7 | 0.0175 | |||
| AMPb | Below limit of detection | −1.4 | 0.0477 | |||
| Hypoxanthineb | 1.4 | 0.0573 | 1.4 | 0.2542 | −3.4 | <0.0001 |
| Xanthineb | Below limit of detection | −1.9 | 0.0017 | |||
| Inosineb | Below limit of detection | −2.8 | <0.0001 | |||
| Propionylcarnitineb | Below limit of detection | 86.4 | 0.0480 | |||
| Acetylcarnitineb | Below limit of detection | 2.0 | <0.0001 | |||
aStatistically significant dysregulation in Human PDR
bStatistically significant dysregulation in the OIR mouse